T. Blaettler

发表

234th ENMC International Workshop: Chaperone dysfunction in muscle disease Naarden, The Netherlands, 8–10 December 2017

L. Greensmith, H. Kampinga, R. Bryson-Richardson, 2018, Neuromuscular Disorders.

ACh receptor partial agonist: pharmacological characterization and phase I

D. Hoyer, G. Bilbe, C. Pryce, 2015 .

Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial

E. Mercuri, F. Muntoni, F. Rivier, 2017, The Lancet Neurology.

Carboxy-terminated oligo(ethylene glycol)-alkane phosphate: synthesis and self-assembly on titanium oxide surfaces.

S. Tosatti, M. Textor, E. Jaehne, 2007, Langmuir : the ACS journal of surfaces and colloids.

Looking Back and Looking Forward at Stuff

L. Greensmith, J. Statland, R. Barohn, 2020 .

A case-control study of sporadic Creutzfeldt-Jakob disease in Switzerland: analysis of potential risk factors with regard to an increased CJD incidence in the years 2001–2004

K. Hess, M. Zwahlen, A. Aguzzi, 2009, BMC public health.

Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms

S. Marder, G. Garibaldi, D. Bugarski-Kirola, 2014, Psychiatry Research.

AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation

D. Hoyer, G. Bilbe, K. Lingenhoehl, 2015, British journal of pharmacology.

Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial p

S. Kapur, G. Garibaldi, D. Bugarski-Kirola, 2016, The lancet. Psychiatry.

Bitopertin in Negative Symptoms of Schizophrenia—Results From the Phase III FlashLyte and DayLyte Studies

S. Lawrie, S. Marder, W. Fleischhacker, 2017, Biological Psychiatry.

Defining therapeutic benefit for people with schizophrenia: Focus on negative symptoms

S. Potkin, R. Buchanan, S. Leucht, 2015, Schizophrenia Research.

Efficacy and safety of arimoclomol in Niemann‐Pick disease type C: Results from a double‐blind, randomised, placebo‐controlled, multinational phase 2/3 trial of a novel treatment

M. Patterson, R. D. Da Riol, M. Gautschi, 2021, Journal of inherited metabolic disease.

Efficacy and safety of adjunctive bitopertin (10 and 20mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics — Results from the Phase III FlashLyte Study

S. Marder, W. Fleischhacker, C. Arango, 2014, Schizophrenia Research.

Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial

L. Greensmith, J. Albayda, J. Statland, 2023, The Lancet Neurology.

Bitopertin in Negative Symptoms of Schizophrenia—Results From the Phase III FlashLyte and DayLyte Studies

S. Lawrie, S. Marder, W. Fleischhacker, 2017, Biological Psychiatry.